Research graph
References from Multimodal Artificial Intelligence Predicts Pathological Response and Prognosis in HER2-Positive Early Breast Cancer Treated with Chemotherapy De-escalation Strategies: Analyses from PHERGain and PHERGain-2 Trials. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s1470-2045(11)70336-9
10.1016/s1470-2045(11)70336-9 · External reference
10.1200/jco.20.01204
10.1200/jco.20.01204 · External reference
Chemotherapy-induced peripheral neuropathy in breast cancer: a narrative review
10.21037/tbcr-25-41 · 2026 · External reference
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
10.1016/s1470-2045(21)00122-4 · 2021 · External reference
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
10.1016/s0140-6736(24)00054-0 · 2024 · External reference
A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study
10.1016/j.annonc.2026.01.013 · 2026 · External reference
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial
10.1158/1078-0432.ccr-24-0464 · 2024 · External reference
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
10.1016/j.ebiom.2021.103801 · 2022 · External reference
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
10.1016/s1470-2045(25)00276-1 · 2025 · External reference
Ashworth A. Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology
10.1038/s41523-023-00518-1 · 2023 · External reference
Artificial Intelligence in Oncology: Clinical Applications, Challenges, and Opportunities
10.1200/edbk-26-520716 · 2026 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
